Korean J Fam Pract 2020; 10(5): 324-331  https://doi.org/10.21215/kjfp.2020.10.5.324
Immunization for Adults
Jin Young Hwang1, Hee-Taik Kang1,2,*
1Department of Family Medicine, Chungbuk National University Hospital; 2Department of Family Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
Hee-Taik Kang
Tel: +82-43-261-6309, Fax: +82-43-269-6675
E-mail: kanght0818@gmail.com
ORCID: https://orcid.org/0000-0001-8048-6247
Received: April 17, 2020; Revised: July 13, 2020; Accepted: July 29, 2020; Published online: October 20, 2020.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Global life expectancy has increased with the development of medicine, and better nutrition, hygiene, and health care. However, as the elderly population increases, the number of people who are immunocompromised and who have chronic diseases has also increased. New infectious diseases have also become a significant threat to public health. In particular, pathogens can have fatal consequences in the elderly and people with underlying diseases. Vaccination is an effective and safe means of preventing infectious diseases, and adult vaccination has gained increasing interest in recent years. The increased number of people with chronic diseases and underlying health conditions is a consequence of the aging population. Furthermore, the decline in immunity after immunization in childhood and adolescence, emergence of novel infectious diseases, change in epidemiology due to mutant microorganisms, and increased infectious diseases from overseas have all increased the need for adult vaccination.
Keywords: Immunization; Infectious Disease; Immunity; Vaccination
  1. Korea Centers for Disease Control and Prevention. 2018 Guidelines for adults immunization. 2nd ed. Cheongju: Korea Centers for Disease Control and Prevention; 2018.
  2. World Health Organization. Seasonal influenza fact sheet [Internet]. Geneva:World Health Organization; 2018 [cited 2020 Mar 20].
  3. Nelson MI, Holmes EC. The evolution of epidemic influenza. Nat Rev Genet 2007; 8: 196-205.
    Pubmed CrossRef
  4. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8: 81-8.
    Pubmed KoreaMed CrossRef
  5. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018; 392: 2313-24.
  6. Korea Centers for Disease Control and Prevention. Epidemiology and management of vaccine preventable disease. 5th ed. Cheongju: Korea Centers for Disease Control and Prevention; 2017.
  7. Moore LSP, Leslie A, Meltzer M, Sandison A, Efstratiou A, Sriskandan S. Corynebacterium ulcerans cutaneous diphtheria. Lancet Infect Dis 2015; 15:1100-7.
  8. Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis 2000; 181 Suppl 1: S110-5.
    Pubmed CrossRef
  9. Centers for Disease Control and Prevention. Pertussis (whooping cough) [Internet]. Atlanta: Centers for Disease Control and Prevention; 2019 [cited 2020 Mar 20].
  10. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86: 88-93.
    Pubmed KoreaMed CrossRef
  11. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60: 900-9.
    Pubmed KoreaMed CrossRef
  12. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
    Pubmed CrossRef
  13. Tseng HF, Schmid DS, Harpaz R, LaRussa P, Jensen NJ, Rivailler P, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine. Clin Infect Dis 2014; 58: 1125-8.
    Pubmed KoreaMed CrossRef
  14. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-96.
    Pubmed CrossRef
  15. Centers for Disease Control and Prevention. Pneumococcal disease [Internet]. Atlanta: Centers for Disease Control and Prevention; 2019 [cited 2020 Mar 20].
  16. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-25.
    Pubmed CrossRef
  17. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68: 1069-75.
    Pubmed KoreaMed CrossRef
  18. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3: S3/11-25.
    Pubmed CrossRef
  19. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11: 1048-56.
  20. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM;ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-9.
    Pubmed CrossRef
  21. Centers for Disease Control and Prevention. Human papillomavirus (HPV) [Internet]. Atlanta: Centers for Disease Control and Prevention; 2019 [cited 2020 Mar 20].
    Available from: https://www.cdc.gov/hpv/
  22. Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J Korean Med Sci 2012; 27:1091-7.
    Pubmed KoreaMed CrossRef
  23. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Suppl 5: F123-38.
    Pubmed KoreaMed CrossRef
  24. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014; 13: 1279-90.
    Pubmed CrossRef
  25. Kim KA, Lee A, Ki M, Jeong SH. Nationwide seropositivity of hepatitis A in Republic of Korea from 2005 to 2014, before and after the outbreak peak in 2009. PLoS One 2017; 12: e0170432.
    Pubmed KoreaMed CrossRef
  26. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR; Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease:recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 608-12.
    Pubmed CrossRef

This Article

Author ORCID Information

Funding Information

Social Network Service